

BRIEF QUESTIONS AND ANSWERS ON CURRENT CLINICAL CONTROVERSIES

.....

Q: What is the optimal strategy for colon cancer surveillance in patients with ulcerative colitis?

WILLIAM M. BAUER, MD

Center for Inflammatory Bowel Disease, Department of Gastroenterology, Cleveland Clinic

BRET A. LASHNER, MD, MPH

Director, Center for Inflammatory Bowel Disease, Department of Gastroenterology, Cleveland Clinic

ALTHOUGH THE ASSOCIATION between inflammatory bowel disease and colorectal cancer is well known, the optimal strategy (number of colonoscopies, interval between exams, biopsy protocol) for screening these patients to detect colorectal cancer early is not clear.

For another clinician's perspective on colorectal cancer screening, see page 303.

Until more evidence is gathered, we recommend that patients with ulcerative colitis undergo a colonoscopy every 1 to 3 years. During these procedures, biopsy samples should be taken every 10 cm along the length of the colon, and if *any* of these samples reveals dysplasia, a total proctocolectomy should be performed.¹

RATIONALE

Persons with inflammatory bowel disease have a lifetime risk of colorectal cancer at least twice as high as in the general population. Moreover, they tend to develop colorectal cancer much earlier in their lives than do people with sporadic colon cancer. The longer the person has had inflammatory bowel disease and the more extensive it is, the greater the risk.^{2–4} (However, proctitis poses no increase in risk for rectal cancer.)

Frequency of colonoscopies

Since the risk of dysplasia or cancer increases with the duration of ulcerative colitis, testing should be done more frequently as time goes on.⁵ One method calls for testing every 3 years for the first 20 years of disease, every 2 years for the next 10 years, and every year thereafter.¹ Such an approach provides for at least 20 examinations in 40 years. Most of the evaluations would be performed in the later years when the risk is the highest.

A history of primary sclerosing cholangitis adds significantly to the already high risk of dysplasia and colorectal cancer in patients with ulcerative colitis. Therefore, at the same duration of disease, patients with primary sclerosing cholangitis should be tested more often, perhaps every year.^{3,5,6} For these patients, prophylactic colectomy may offer the best alternative in terms of life expectancy.^{7,8}

Biopsy protocol

Surveillance programs in patients with ulcerative colitis can be expected to detect neoplasia at an early stage and decrease mortality related to cancer.⁹ However, colonoscopy with multiple biopsies as a testing method is problematic.

Because dysplasia can be present focally as well as diffusely, biopsies must be taken throughout the colon. The sensitivity of testing for detecting dysplasia is increased with a greater number of biopsies taken. Therefore, biopsy samples should be taken every 10 cm.

Any biopsy that is positive for dysplasia poses an inordinately high risk: the risk of concurrent cancer is 19% in patients with low-grade dysplasia, and 42% in patients with high-grade dysplasia.¹⁰ Therefore, a total proctocolectomy is recommended for all patients with low-grade dysplasia, highgrade dysplasia, or cancers found at colonoscopy.

Research is ongoing to determine alternative markers of malignancy to improve the sensitivity of the present surveillance regimens. The optimal strategy is not clear, but screening should be frequent CONTINUED FROM PAGE 273

REFERENCES

- 1. Lashner BA. Recommendations for colorectal cancer screening in ulcerative colitis: A review of research from a single university-based surveillance program. Am J Gastroenterol 1992; 87:168-175.
- Greenstein A, Sachar D, Pucillo A, et al. Cancer in universal and left sided ulcerative colitis: Clinical and pathologic features. Mt Sinai J Med 1981; 46:25-32.
- 3. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: A cohort study of primary referrals from three centres. Gut 1988; 29:206-217.
- 4. Mir-Madilessi SH, Farmer RG, Easley KA, et al. Colorectal and extracolonic malignancy in ulcerative colitis. Cancer 1986; 58:1569-1574.
- 5. Lashner BA, Hanauer SB, Silverstein MD. Optimal timing of colonoscopy to screen for cancer in ulcerative colitis. Ann Intern Med 1988; 108:274-278.
- Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and 6. colorectal cancer. A population-based study. N Engl J Med 1990; 323:1228-1233.
- 7. Marchesa P, Lashner BA, Lavery IC, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997; 92:1285-1288.
- 8. Loftus EV, Sandborn WJ, Tremaine WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology 1996; 110:432-440.
- 9. Provenzale D, Kowdley KV, Arora S, et al. Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology 1995; 109:1188–1196.
- 10. Shapiro BD, Lashner BA. Cancer biology in ulcerative colitis and potential use in endoscopic surveillance. Gast Endo Clin North Am 1997; 7:453-468.

NNOUNCI

The Alpha One Foundation **Research Registry** for individuals diagnosed with

Alpha,-Antitrypsin Deficiency

Enroll your patients in the Alpha One Research Registry, the only one of its type in the United States. Patients and their physician

will have an opportunity to participate in clinical trials and research protocols to develop new therapies.

All data is confidential and managed by the University of Miami School of Medicine Department of Epidemiology and Public Health

For Patient Enrollment Call 1-888-825-7421 Ext.6

Visit The Alpha One Foundation on the Web at www.alphaone.org or E-mail us at registry @ alphaone.org

NEW FEATURE **1-MINUTE CONSULT**

What questions do you want answered?

We want to know what questions you want addressed in "1-Minute Consult." All questions should be on practical, clinical topics. You may submit questions by mail, phone, fax, or e-mail.

Name	С РН
Address	2
City	2
StateZip	CC
Phone	
Fax	
E-mail	



We cannot return materials sent and cannot guarantee that all questions will be part of the series. Questions may be edited or recast. Submission of a question constitutes permission for the *Cleveland Clinic Journal of Medicine* to publish it in various editions and forms.



BRIEF OUESTIONS AND ANSWERS **ON CURRENT** CLINICAL CONTROVERSIES

Cleveland Clinic Journal of Medicine 9500 Euclid Ave., EE37 eveland, OH 44195

HONE 16 • 444 • 2661 XA 16 · 444 · 9385 MAIL

jm@ccf.org

